Action Required: Password Reset on Next Login

As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.

To reset your password, please visit the Reset Password page.

We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.

BioCentury
ARTICLE | Finance

Cardior’s €64M B round to push first-in-class heart failure program into Phase II

German company’s goal is disease-modification, a sign of lead investor Inkef Capital’s growing ambition in life sciences.  

August 26, 2021 12:39 AM UTC

With a large series B round in hand, Cardior can now push its first-in-class lead program through Phase II proof of concept to determine whether inhibiting miR-132 can really be the first disease-modifying therapy for heart failure.

Germany cardiovascular company Cardior Pharmaceuticals GmbH raised €64 million ($75 million) in a round led by new investor Inkef Capital. The company previously raised €15 million in a series A round in 2017...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article